New York, June 15, 2015 -- Immuno-oncology drugs are credit positive for key players in the pharmaceutical industry, including Bristol-Myers Squibb, Merck & Co., Inc., Roche Holdings and AstraZeneca, Moody's Investors Service says in a new report. Bristol-Myers Squibb is currently the leader in the development and commercialization of the new drugs, but competitors are not far behind.

Vollständigen Artikel bei Moodys lesen